]>
IRCT201710089014N193 IRCT 2017-10-17 Vice-chancellor for Research and Technology, Zahedan University of Medical Sciences Comparison of the therapeutic effect of allopurinol versus placebo on clinical signs and symptoms in patients with manic bipolar disorder Comparison of the therapeutic effect of allopurinol versus placebo on clinical signs and symptoms in patients with manic bipolar disorder: a double blind randomized clinical trial 2007-10-23 anticipated 60 Complete https://irct.ir/trial/9631 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: Randomization: The patients will be randomly assigned to intervention and control groups using block randomization. Blinding: Patients will be unaware of the type of intervention. The physician who will examine the patients will not be aware of the intervention. Therefore, the trial will be run as double blind. 2 Manic bipolar disorder. Intervention 1: Intervention group: Routine treatment plus allopurinol 300 mg twice a day orally for 4 weeks. Intervention 2: Control group: Routine treatment plus placebo capsule (including cellulose) twice a day orally for 4 weeks.
public Mozhdeh Rigi
Baharan Hospital, Imam Khomeini Ave.
Zahedan Iran (Islamic Republic of) +98 37 7933 5154 rigi.mozhdeh@gmail.com Baharan Hospital scientific Dr Mohammad Davood Mohebi
Baharan Hospital, Imam Khomeini Ave.
Zahedan Iran (Islamic Republic of) +98 37 7933 5154 mdmohebi@gmail.com Baharan Hospital Iran (Islamic Republic of) Inclusion criteria: Age of 18 to 45 years; manic bipolar disorder; Score of YMRS equal to or greater than28. Exclusion criteria: Pregnancy; breastfeeding; sensitivity to allopurinol; mental disability; diabetes; hypertension; hypothyroiditis; hyperthyroiditis; convulsion; liver failure; renal failure. 18 years 45 years Both F30 Manic episode Treatment - Drugs Placebo Intervention group: Routine treatment plus allopurinol 300 mg twice a day orally for 4 weeks. Control group: Routine treatment plus placebo capsule (including cellulose) twice a day orally for 4 weeks. Severity of clinical signs and symptoms. Timepoint: Before intervention and one, two, three, and four weeks after intervention. Method of measurement: Using YMRS questionnaire. Vice-chancellor for Research and Technology, Zahedan University of Medical Sciences Approved 2017-09-24 Ethics Committee of Zahedan University of Medical Sciences Vice-chancellor for Research and Technology, Zahedan University of Medical Sciences, Dr Hesabi Square Zahedan Iran (Islamic Republic of)